Author: Norgine Limited

Posted Date:

May 5, 2026

Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1

Norgine Limited

May 5, 2026
Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union

Norgine Limited

April 29, 2026
Norgine announces £23 million new investment as part of more than £50 million committed to expanding medicines manufacturing in Wales

Norgine Limited

March 5, 2026